Your search returned 6 results. Subscribe to this search

Not what you expected? Check for suggestions
|
1. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

by Joshi A | Joshi A | Patil V | Noronha V | Chougule A | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding author].

In Lung India
Material type: article Article; Format: print Publisher: 2018Availability: Items available for loan: Tata Memorial Hospital (1).

2. P3.02b-007 Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung

by Goel A | Joshi A | Patil V | Noronha V | Chougule A | Mahajan A | Janu A | Kaushal R | Goud S | More S | Karpe A | Ramaswamy A | Pande N | Chandrasekharan A | Talreja V | Chanana R | Prabhash K.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

3. P3.02b-090 Pemetrexed versus gefitinib in egfr mutation positive lung cancer: results of a phase 3 study from India

by Kumar Prabhash | Patil V | Joshi A | Noronha V | Chougule A | Mahajan A | Janu A | Goud S | More S | Kaushal R | Karpe A | Ramaswamy A | Pande N | Talreja V.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: New York, NY : Elsevier 2017Online access: PDF Availability: Items available for loan: Tata Memorial Hospital (1).

4. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

by Patil VM | Noronha V | Joshi A | Choughule AB | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding author].

In ESMO Open
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

5. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/ carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer

by Patil V | Noronha V | Joshi A | Chougule A | Bhattacharjee A | Goel A | Talreja V | Menon N | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Mahajan A | Janu A | Purandare N | Kumar P [Corresponding Author].

In Cancer Research, Statistics, and Treatment
Material type: article Article; Format: print Publisher: 2019Availability: Items available for loan: Tata Memorial Hospital (1).

6. Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial

by Noronha V | Pandey A | Patil V | Joshi A | Choughule AB | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding author].

In Indian Journal of Medical and Paediatric Oncology
Material type: article Article; Format: print Publisher: 2018Availability: Items available for loan: Tata Memorial Hospital (1).

Powered by Koha